

INVESTIGATION OF ACETAMINOPHEN CONTENT IN OVER-THE-COUNTER
MEDICINE SOLD IN JOHOR BAHRU, MALAYSIA

NURUL SYAMEEM BINTI ZAINAL

A dissertation submitted in partial fulfilment of the
requirements for the award of the degree of
Master of Science (Forensic Science)

Faculty of Science
Universiti Teknologi Malaysia

JANUARY 2019

DEDICATION

This dissertation is dedicated to my parents and siblings after all their endless support and love.

ACKNOWLEDGEMENT

I would like to express my deepest gratitude to my supervisor Dr. Aemi Syazwani Abdul Keyon for her useful comments, remarks and engagement through the learning process of this research project. Furthermore, I would like to thank the other Forensic Science lecturers for giving me knowledge and better understanding of the Forensic Science.

I am also indebted to Universiti Teknologi Malaysia (UTM) for providing all the facilities throughout my studies. I would like to thank the lab and faculty staffs after all the help they have given.

My fellow classmates should also be recognised for their support. My sincere appreciation also extends to all my everyone who have provided assistance at various occasions. Their views and tips are useful indeed.

And finally to my family who I know will always be right behind me, thank you.

ABSTRACT

The market of counterfeit medicine is slowly growing making more people to be exposed with these kind products. Counterfeit medicine can bring many adverse effects to health as well as social and economic wise. The purpose of this study is to investigate the content of over-the-counter (OTC) paracetamol that were sold in Johor Bahru area. With the growing market for substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) products including medicinal products, the statuses of these paracetamol tablets sold in market can raise some doubts. For that matter, generic OTC paracetamol 650 mg tablets brand A was chosen to be investigated. The tablets were sampled from three different type of premises namely convenient stores X, pharmacies and traditional medicine stores in four different municipal districts of Majlis Bandaraya Johor Bahru (MBJB): Pulai, Tebrau, Johor Bahru and Pasir Gudang. A few examinations and analyses were conducted to achieve this goal: a) qualitative screening examinations of product packaging (hologram and blister packaging) using Video Spectral Comparator (VSC) instrument to distinguish any SSFFC products, b) chemical profiling the ingredients of the products using Attenuated Total Reflectance – Fourier Transform Infrared (ATR-FTIR) spectroscopy to detect the presence of active pharmaceutical ingredient (API) and c) quantitative analysis of the amount of API using High Performance Liquid Chromatography coupled with Diode-Array Detector (HPLC-DAD) and the method was validated. Visual inspection of the packaging showed that apart from sample PGKU 2, all samples came from genuine source was suggested. The second screening process using ATR-FTIR found that all samples contained API as claimed (within the range of 95-105%). HPLC-DAD findings showed that the content of paracetamol could be divided into three; 1) within the range (625.14 – 671.62 mg), 2) below the range (400.87 – 616.73 mg) and 3) above the range (700.53 – 1147.50 mg). Based on these findings, each of the sample then was classified into three categories of SSFFC, that were substandard, unregistered/unlicensed and falsified. No sample was identified as unregistered/unlicensed. One sample, PGKU 2 was classified as falsified meanwhile the remaining samples were identified as substandard. In conclusion, the output of this study can be used to regulate and pharmaceutical companies and to monitor the SSFFC market.

ABSTRAK

Pasaran bagi bahan ubatan tiruan semakin membesar dan menyebabkan lebih ramai orang terdedah kepada produk ini. Barangan ubatan tiruan boleh memberi banyak kesan buruk dari segi kesihatan serta dari segi ekonomi dan sosial. Tujuan kajian ini dijalankan adalah untuk menyiasat kandungan ubat atas kaunter (OTC) *acetaminophen* atau lebih dikenali umum sebagai *paracetamol*. Dengan perkembangan pasaran bagi barangan tiruan (SSFFC) yang semakin membesar termasuk bahan produk kesihatan telah menimbulkan keraguan dalam status keasliannya. Oleh demikian itu, ubat OTC generik *paracetamol* 650 mg jenama A telah disampel di tiga jenis kedai iaitu kedai serbaneka “X”, farmasi dan kedai ubat tradisional di empat daerah Majlis Bandaraya Johor Bahru (MBJB): Pulai, Tebrau, Johor Bahru dan Pasir Gudang. Beberapa pemeriksaan dan analisis telah dijalankan untuk mencapai matlamat kajian: a) pemeriksaan pembungkusan produk (hologram dan pembungkusan blister) menggunakan alat *video spectral comparator* (VSC), b) pemprofilan kimia bahan-bahan produk menggunakan spektroskopi transformasi Fourier inframerah (ATR-FTIR) dan c) kuantitatif analisis kandungan bahan aktif farmaseutikal (API) menggunakan kromatografi cecair berprestasi tinggi (HPLC-DAD). Pemeriksaan visual pembungkusan menunjukkan semua sampel adalah asli selain dari sampel PGKU 2. Pemeriksaan kedua menggunakan ATR-FTIR telah menjumpai API seperti yang dinyatakan (dalam lingkungan 95 – 105%). Keputusan HPLC-DAD menunjukkan kandungan paracetamol boleh dikategorikan kepada tiga; 1) dalam lingkungan (625.14 – 671.62 mg), 2) bawah lingkungan (400.87 – 616.73 mg) dan 3) atas lingkungan (700.53 – 1174.50 mg). Berdasarkan keputusan semua analisis, setiap sampel akan diklasifikasi kepada tiga kategori; substandard, tidak berdaftar/tidak berlesen dan palsu. Tiada sampel yang dikenali sebagai tidak berdaftar/tidak berlesen. Satu sampel, PGKU 2 dikenali sebagai palsu dan selebihnya dikenali sebagai substandard. Kesimpulannya, keputusan yang diperolehi dari analisis ini dapat membantu pihak berkuasa untuk mengawal selia syarikat farmaseutikal dan memantau pasaran SSFFC.

TABLE OF CONTENTS

	TITLE	PAGE
	DECLARATION	ii
	DEDICATION	iii
	ACKNOWLEDGEMENT	iv
	ABSTRACT	v
	ABSTRAK	vi
	TABLE OF CONTENTS	vii
	LIST OF TABLES	x
	LIST OF FIGURES	xi
	LIST OF ABBREVIATIONS	xiii
	LIST OF SYMBOLS	xiv
	LIST OF APPENDICES	xv
CHAPTER	1 INTRODUCTION	1
	1.1 Problem background	1
	1.2 Problem statement	2
	1.3 Research goals	3
	1.3.1 Research objectives	3
	1.4 Scope of study	4
	1.5 Significance of study	4
CHAPTER	2 LITERATURE REVIEW	5
	2.1 Substandard/ Spurious/ Falsely labelled/ Falsified/ Counterfeit (SSFFC) medicines	5
	2.1.1 Definitions of SSFFC medicines	5
	2.1.2 Counterfeiting of pharmaceutical products: A worldwide phenomena	6
	2.1.3 Occurrences in Malaysia	8
	2.1.4 Consequences of SSFFC medicines	9

	2.1.4.1 Public health consequences	9
	2.1.4.2 Economic and social consequences	10
	2.1.5 Analytical techniques for determining SSFFC medicines	10
	2.2 Paracetamol	11
	2.2.1 Visual examinations of counterfeit medicines	13
	2.2.2 Analytical techniques for determining paracetamol	13
	2.2.2.1 Infrared spectrometer	14
	2.2.2.2 High performance liquid chromatography	15
CHAPTER	3 RESEARCH METHODOLOGY	17
	3.1 Introduction	17
	3.1.1 Sampling design and collection	18
	3.1.2 Chemicals and apparatus	20
	3.1.3 Visual inspection using Video Spectral Comparator	21
	3.1.3.1 Meditag™ hologram examination	22
	3.1.3.2 Examination of blister packaging and tablet	22
	3.1.4 Tablet sample preparation for qualitative and quantitative analyses	23
	3.1.5 Preparation of standard working solution	24
	3.1.6 ATR-FTIR spectroscopy analysis	24
	3.1.7 HPLC-DAD analysis	25
CHAPTER	4 RESULT AND DISCUSSION	27
	4.1 Visual inspections of hologram and blister packaging	27
	4.1.1 Authenticity confirmation using hologram	27
	4.1.2 Blister packaging examination	33
	4.2 Chemical Profiling using ATR-FTIR	38

4.3	Quantitative Analysis using HPLC	41
4.3.1	Method validation	42
4.3.2	Quantitation of paracetamol in a tablet	45
4.4	Statistical Analysis using SPSS	51
4.5	Classification of sample	52
CHAPTER	5 CONCLUSION AND RECOMMENDATIONS	55
5.1	Conclusion	56
5.2	Recommendations	52
REFERENCES		57
APPENDICES		65

LIST OF TABLES

TABLE NO.	TITLE	PAGE
Table 2.1	Summary of HPLC method for determining paracetamol developed by other authors.	16
Table 3.1	List of sample code names.	19
Table 3.2	List of chemicals.	20
Table 3.3	List of apparatus.	20
Table 3.4	List of instruments, software and mobile application.	21
Table 3.5	Parameter and settings of VSC for Meditag™ 3.	22
Table 3.6	Parameters and setting set up of VSC for blister packaging.	23
Table 3.7	ATR-FTIR parameters setting.	24
Table 3.8	Conditions set up for HPLC-UV	25
Table 4.1	List of characteristics of all samples.	35
Table 4.2	List of functional groups detected in standard paracetamol spectrum (Skoog, Holler, & Crouch, 2007).	39
Table 4.3	Analytical figures of merit	42
Table 4.4	Accuracy and intra-day and inter-day precision.	44
Table 4.5	Summary of paracetamol content (mg) of each sample.	47

LIST OF FIGURES

FIGURE NO.	TITLE	PAGE
Figure 2.1	Classification of SSFFC products (World Health Organization, 2015).	6
Figure 2.2	Molecular structure of paracetamol.	11
Figure 2.3	Features of authentic and counterfeit paracetamol brand Biogesic 500 mg released by FDA Philippines (Adel, 2018).	12
Figure 2.4	Close Agreement Of Reference Paracetamol Spectra (Red) With Crushed Tablet Spectra (Blue) (Lawson Et Al., 2014)	14
Figure 3.1	The overall outline of the study.	17
Figure 3.2	Sampling locations within MBBB areas which include (A) Pulau, (B) Tebrau, (C) Pasir Gudang and (D) Johor Bahru (reference: Google Earth, https://www.google.com/maps/@1.5696775,103.7674943,37115m/data=!3m1!1e3).	18
Figure 3.3	The summary of sampling locations the samples were bought.	19
Figure 4.1	Enhancement of security features on Meditag™ 3 hologram provided by MOH (Hanafi, 2016).	28
Figure 4.2	Security features of hologram sample TP 2 observed under OVD Viewer.	29
Figure 4.3	Security features of hologram sample PGP 3 observed under OVD Viewer.	30
Figure 4.4	Security Features of Hologram Sample PGKU 1 Observed Under OVD Viewer	31
Figure 4.5	Outputs given by the application checker along with the serial number.	32
Figure 4.6	Characteristics of genuine and registered product for TP 1 in terms of foil pattern, tablet colour and font visibility.	33
Figure 4.7	Characteristics of PGKU 2 sample in terms of foil pattern, tablet colour and font visibility.	34
Figure 4.8	Differences in sample PGKU 2 (left) and sample reference (right) when compared side by side in terms of font visibility.	37

Figure 4.9	Differences in sample PGKU 2 (left) and sample reference (right) when compared side by side in terms of foil pattern.	37
Figure 4.10	Spectrum of standard paracetamol (98% purity) obtained from ATR-FTIR.	38
Figure 4.11	Molecular structure of paracetamol	38
Figure 4.12	ATR-FTIR spectra of standard paracetamol (98% purity) and (below) sample reference, TP 1.	39
Figure 4.13	Split view of ATR-FTIR spectra (top) standard paracetamol (98% purity), (middle) sample reference, TP 1 and (bottom) sample PGKU 2.	40
Figure 4.14	Overlay of ATR-FTIR spectra of two samples; (red) PGKU 2 and (blue) sample reference, TP 1.	41
Figure 4.15	Chromatogram of paracetamol standard. Separation conditions: column: ZORBAX Eclipse Plus C ₁₈ (150 × 4.6 mm, 5µm); mobile phase: methanol:water (1:3); flow rate: 1.5 mL/min; injection volume: 5 µL; wavelength: 243 nm.	43
Figure 4.16	Calibration curve for paracetamol standard (98% purity).	44
Figure 4.17	Chromatogram of one of the sample (sample TKU 1). Separation conditions: column: ZORBAX Eclipse Plus C ₁₈ (150 × 4.6 mm, 5µm); mobile phase: methanol:water (1:3); flow rate: 1.5 mL/min; injection volume: 5 µL; wavelength: 243 nm.	45
Figure 4.18	Graph representing mass of paracetamol in one tablet sampled each premise in Johor Bahru city centre area.	49
Figure 4.19	Graph representing mass of paracetamol in one tablet sampled each premise in Pulai area.	49
Figure 4.20	Graph representing mass of paracetamol in one tablet sampled each premise in Pasir Gudang area.	50
Figure 4.21	Graph representing mass of paracetamol in one tablet sampled each premise in Tebrau area.	50
Figure 4.22	Summary of SSFFC product definitions and list of samples under each category.	54

LIST OF ABBREVIATIONS

API	-	Active Pharmaceutical Ingredient
ATR-FTIR	-	Attenuated Total Reflectance Fourier Transform Infrared
CDCR	-	Control of Drugs and Cosmetic Regulation
DCA	-	Drug Control Authorities
HCA	-	Hierarchical Cluster Analysis
HPLC	-	High Performance Liquid Chromatography
ICH	-	International Conference on Harmonization
LOD	-	Limit of Detection
LOQ	-	Limit of Quantification
MBJB	-	Majlis Bandaraya Johor Bahru
MOH	-	Ministry of Health
NPCB	-	National Pharmaceutical Control Bureau
NRRA	-	National or Regional Regulatory Authority
OTC	-	Over The Counter
OVD	-	Optically Variable Device
PCA	-	Principle Components Analysis
R&D	-	Research and Development
SSFFC	-	Substandard/Spurious/Falsely-labelled/Falsified/Counterfeit
USP	-	United States Pharmacopoeia
UTM	-	Universiti Teknologi Malaysia
VSC	-	Video Spectral Comparator
WHO	-	World Health Organization

LIST OF SYMBOLS

k	-	Retention factor
t_0	-	Dead time
t_r	-	Retention time of analyte
σ	-	Standard deviation of the y-intercepts of regression lines
S	-	Slope of the calibration curve

LIST OF APPENDICES

APPENDIX	TITLE	PAGE
Appendix A	Average mass of Brand A tablets before grinded into powder	65
Appendix B	ATR-FTIR spectra for every sample	66
Appendix C	Statistics SPSS ver. 24 result	70
Appendix D	Paracetamol content calculation	72

CHAPTER 1

INTRODUCTION

1.1 Problem Background

One of the most common over-the-counter (OTC) medicine that can be obtained in Malaysia is acetaminophen or commonly known as paracetamol. It is often prescribed to treat fever, mild pain relief, muscular aches, migraine headache and osteoarthritis. A survey conducted in Penang, Malaysia showed that 75% of consumers used it for headache, and 72% of them used it for fever (Chong, Tan, & Chooi, 2017).

Since paracetamol is a cheap OTC drug that is easily obtained, it is prone to be counterfeited. Counterfeiting medicines are a serious crime. Currently there is no universally accepted definition of counterfeit medicines. World Health Organization (WHO) is currently using the term ‘substandard/spurious/falsely-labelled/falsified/counterfeit’ or abbreviated as SSFFC for medical products, and these products are categorized into three sub-groups; substandard, unregistered and falsified (World Health Organization). On the other hand, counterfeit medicine defined by U.S Food & Drug Administration (FDA) is fake medicine that may be contaminated or contain none or wrong active ingredient, or could have the correct active ingredient but at the wrong dose (U.S Food & Drug). Pharmaceutical Security Institute in 2011 reported that Asia has 40% pharmaceutical crime reported (Stevens & Mydin, 2013). According to a report by Ministry of Health (MOH) Malaysia, 5.2% of medicines sold over-the-counter are fake medicine (Zulkifli *et al.*, 2016). Fake medicines possess many risky problems that can affect an individual’s health. It may contain harmful toxic contaminants such as heavy metals (arsenic or lead) which are carcinogenic and toxic to human bodies (Stevens & Mydin, 2013). In 1995, a large number of children was admitted to hospital due to renal failure in Bangladesh due to paracetamol elixir containing diethylene glycol

(Hanif et al., 1995). The prices of fake medicines are usually lower than the standard pricing, hence consumers are more likely to purchase the fake medicines causing a substantial loss percentage for the pharmaceutical industry (Blackstone, Fuhr, & Pociask, 2014).

Several technologies are being used to combat these problems. It includes as the usage of visible markers or holograms, barcodes, 2D datamatrix code and radiofrequency identifications (Hall, 2012). In 2005, Malaysia introduced Meditag™ program that requires all Drug Control Authorities (DCA) registered products to bear holographic security device (Zulkifli *et al.*, 2016). On the other hand, several techniques have been used to determine paracetamol content in pharmaceutical formulations or biological samples. For examples; Fourier transform infrared spectroscopy (FTIR) with the result of percentage recovery between 98% to 99% in solid paracetamol samples (Mallah *et al.*, 2015) and UV-Vis spectrophotometry with percentage recovery between 101.67% to 102.43% in paracetamol and nabumethone combined tablet samples (Rote *et al.*, 2012). Altun (2002) performed analysis of paracetamol using high performance liquid chromatography (HPLC) with percentage recovery of 101.62% in a mixture of paracetamol, caffeine and dipyron samples, while Calinescu *et al.* (2012) obtained recovery results in the range 99.6% to 102.8% in paracetamol and its impurities samples using the same instrument.

This present study, a few examinations were conducted to investigate the status of OTC paracetamol tablets Brand A that were sold in four municipal districts of Majlis Bandaraya Johor Bahru (MBJB); Pulai, Tebrau, Johor Bahru and Pasir Gudang. With the ever-growing population people living in MBJB areas, more people are exposed with the risk of getting SSFFC products on their hands.

1.2 Problem Statement

Amount of SSFFC medical products are on the rise on the market despite many efforts being done by the authorities to combat it. Falsified or substandard medicines can bring many adverse health effects towards its consumers, as well as

economic effects (Aminu & Gwarzo, 2017; Burki, 2010; Newton *et al.*, 2010). Due to its lower prices as compared to its genuine products, the public tend to choose the fake instead (Dégardin *et al.*, 2014). Lacked information on qualitative and quantitative analyses regarding these SSFFC medicines making the public to be less aware of these rising problems. Up until 2018, there is no study have been done on the status of Brand A whether in Johor Bahru or Malaysia. This study will help to provide more information on the status of paracetamol tablets and to bring more awareness towards the public.

1.3 Research Goals

1.3.1 Research Objectives

The aim of the study is to investigate on the content of over the counter (OTC) paracetamol that were sold in Johor Bahru, Malaysia. The objectives of the research are:

- (a) To qualitatively screen packaging and the tablet of paracetamol 650 mg Brand A using Video Spectral Comparator instrument for distinguishing any possible SSFFC products
- (b) To qualitatively screen the active and non-active ingredients of paracetamol 650 mg Brand A by using Attenuated Total Reflectance – Fourier Transform Infrared Spectroscopy instrument.
- (c) To quantitatively determine the amount of active ingredient (acetaminophen) in paracetamol 650 mg Brand A using High Performance Liquid Chromatography coupled with Diode-Array Detector.

1.4 Scopes of study

This present research is involving paracetamol 650 mg tablet brand A acquired from different type of premises namely convenient stores X, pharmacies and traditional medicine stores. Four municipal districts of MBBJ were chosen as sampling locations. This study was conducted from September until December 2018. Regardless multiple contacts were made concerning getting direct samples manufacturers of paracetamol 650 mg Brand A, no response was given. Screening of the sample packaging was done using Video Spectral Comparator (VSC) to check for its authenticity. Chemical profiling of the sample was also done using Attenuated Total Reflectance – Fourier Transform Infrared Spectroscopy (ATR-FTIR). Paracetamol content in the sample also was analyzed and quantitated by using High Performance Liquid Chromatography coupled with Diode-Array Detector (HPLC-DAD). At the end of this study, the samples were classified into three different categories as described by World Health Organization (WHO); substandard, unregistered/unlicensed and falsified.

1.5 Significance of study

Findings that were obtained from this study can be used as a useful data for related authorities to regulate pharmaceutical companies and manufacturers to meet the quality and standards that have been set up. The data also can be used by the authorities to monitor the counterfeit market of medicinal products.

REFERENCES

- Adel, R. (2018). FDA warns public against fake paracetamol | Philstar.com. Retrieved September 29, 2018, from <https://www.philstar.com/headlines/2018/03/26/1800538/fda-warns-public-against-fake-paracetamol>
- Altun, M. L. (2002). HPLC method for the analysis of paracetamol, caffeine and dipyrone. *Turkish Journal of Chemistry*, 26(4), 521–528.
- Aminu, N., & Gwarzo, M. S. (2017). the Eminent Threats of Counterfeit Drugs To Quality Health Care Delivery in Africa: Updates on Consequences and Way Forward. *Asian Journal of Pharmaceutical and Clinical Research*, 10(7), 63. <https://doi.org/10.22159/ajpcr.2017.v10i7.18384>
- Attaran, A., Barry, D., Basheer, S., Bate, R., Benton, D., Chauvin, J., McKee, M. (2012). How to achieve international action on falsified and substandard medicines. *BMJ (Clinical Research Ed.)*, 345, e7381. <https://doi.org/10.1136/bmj.e7381>
- Bate, R., & Attaran, A. (2012). Counterfeit drugs: A growing global threat. *The Lancet*, 379(9817), 685. [https://doi.org/10.1016/S0140-6736\(12\)60289-X](https://doi.org/10.1016/S0140-6736(12)60289-X)
- Blackstone, E. A., Fuhr, J. P., & Pociask, S. (2014). The health and economic effects of counterfeit drugs. *American Health & Drug Benefits*, 7(4), 216–24. <https://doi.org/10.1056/NEJMp038231>
- Bosch, M. E., Sánchez, A. J. R., Rojas, F. S., & Ojeda, C. B. (2006). Determination of paracetamol: Historical evolution. *Journal of Pharmaceutical and Biomedical Analysis*, 42(3), 291–321. <https://doi.org/10.1016/j.jpba.2006.04.007>
- British Pharmacopoeia*. (2012) (7th Edition). London: Copyright Crown.
- Buowari, O. V. (2012). Fake and Counterfeit Drug: A review. *AFRIMEDIC Journal*, 3(2), 1–4. Retrieved from <http://www.ajol.info/index.php/afrij/article/view/86573>
- Burki, T. (2010). The real cost of counterfeit medicines. *The Lancet Infectious Diseases*, 10(9), 585–586. [https://doi.org/10.1016/S1473-3099\(10\)70173-0](https://doi.org/10.1016/S1473-3099(10)70173-0)
- Burns, W. (2006). WHO launches taskforce to fight counterfeit drugs. *Bulletin of the World Health Organization*, 84(9), 689–690. <https://doi.org/10.1590/S0042-96862006000900005>

- Calinescu, O., Badea, I. A., Vladescu, L., Meltzer, V., & Pincu, E. (2012). HPLC separation of acetaminophen and its impurities using a mixed-mode reversed-phase/cation exchange stationary phase. *Journal of Chromatographic Science*, 50(4), 335–342. <https://doi.org/10.1093/chromsci/bmr043>
- Chong, C., Tan, S., & Chooi, W.-T. (2017). An evaluation on consumers' usage pattern of acetaminophen (paracetamol): A multicenter study from Penang, Malaysia. *Archives of Pharmacy Practice*, 8(1), 15–21. <https://doi.org/10.4103/2045-080X.199617>
- de Veij, M., Deneckere, A., Vandenabeele, P., de Kaste, D., & Moens, L. (2008). Detection of counterfeit Viagra® with Raman spectroscopy. *Journal of Pharmaceutical and Biomedical Analysis*, 46(2), 303–309. <https://doi.org/10.1016/J.JPBA.2007.10.021>
- Dégardin, K., Roggo, Y., & Margot, P. (2014). Understanding and fighting the medicine counterfeit market. *Journal of Pharmaceutical and Biomedical Analysis*, 87, 167–175. <https://doi.org/10.1016/j.jpba.2013.01.009>
- Deisingh, A. K. (2005). Pharmaceutical counterfeiting. *Analyst*, 130(3), 271–279. <https://doi.org/10.1039/b407759h>
- ElTantawy, M. E., Bebawy, L. I., & Shokry, R. F. (2014). Chromatographic determination of clopidogrel bisulfate; detection and quantification of counterfeit Plavix® tablets. *Bulletin of Faculty of Pharmacy, Cairo University*, 52(1), 91–101. <https://doi.org/10.1016/J.BFOPCU.2014.04.003>
- European Medicines Agency. (n.d.). Falsified medicines | European Medicines Agency. Retrieved December 27, 2018, from <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/falsified-medicines>
- Fatokun, O. (2016). Curbing the circulation of counterfeit medicines in Nigeria. *The Lancet*, 388(10060), 2603. [https://doi.org/10.1016/S0140-6736\(16\)32121-3](https://doi.org/10.1016/S0140-6736(16)32121-3)
- Food and Drug Administration Republic of the Philippines. (2018). *FDA Advisory No. 2018-081*.
- Ging, P., Mikulich, O., & O'Reilly, K. M. A. (2016). Unexpected paracetamol (acetaminophen) hepatotoxicity at standard dosage in two older patients: time to rethink 1 g four times daily?: Table 1. *Age and Ageing*, 45(4), 566–567. <https://doi.org/10.1093/ageing/afw067>
- Hall, C. (2012). Technology for combating counterfeit medicine, 73–76.

- <https://doi.org/10.1179/204777312X13419245939485>
- Hanafi, N. I. (2016). Current Meditag™ Hologram Security Sticker - PORTAL MyHEALTH. Retrieved October 1, 2018, from <http://www.myhealth.gov.my/en/current-meditagtm-hologram-security-sticker/>
- Hanif, M., Mobarak, M. R., Ronan, A., Rahman, D., Donovan, J. J., & Bennish, M. L. (1995). Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. *BMJ (Clinical Research Ed.)*, *311*(6997), 88–91. <https://doi.org/10.1136/BMJ.311.6997.88>
- Health Sciences Authority. (2015). HSA Seizes More Than 11,000 Units of Illegal Health Products During Week of International Enforcement Operation. Retrieved September 26, 2018, from [http://www.hsa.gov.sg/content/dam/HSA/News_and_Events/Press_Releases/2015/Media Release - HSA seizes more than 11000 units of illegal health products during Ops Pangea_web.pdf](http://www.hsa.gov.sg/content/dam/HSA/News_and_Events/Press_Releases/2015/Media_Release_-_HSA_seizes_more_than_11000_units_of_illegal_health_products_during_Ops_Pangea_web.pdf)
- Hensey, C. C., & Gwee, A. (2016). Counterfeit drugs: an Australian perspective. *The Medical Journal of Australia*, *204*(9), 344. <https://doi.org/10.5694/mja16.00105>
- Hoellein, L., & Holzgrabe, U. (2014). Development of simplified HPLC methods for the detection of counterfeit antimalarials in resource-restraint environments. *Journal of Pharmaceutical and Biomedical Analysis*, *98*, 434–445. <https://doi.org/10.1016/J.JPBA.2014.06.013>
- Hosseini, S. A. R., Darbooy, S., Tehrani Banihashemi, S. A., Naseri, S. M., & Dinarvand, R. (2011). Counterfeit medicines: Report of a cross-sectional retrospective study in Iran. *Public Health*, *125*(3), 165–171. <https://doi.org/10.1016/J.PUHE.2010.11.015>
- International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures: Text and Methodology. (1996). *ICH-Q2B, 1994*(November), 13. https://doi.org/http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
- INTERPOL. (n.d.-a). Operation Pangea. Retrieved September 26, 2018, from <https://www.interpol.int/Crime-areas/Pharmaceutical-crime/Operations/Operation-Pangea>
- INTERPOL. (n.d.-b). Operation Storm. Retrieved September 26, 2018, from <https://www.interpol.int/Crime-areas/Pharmaceutical->

crime/Operations/Operation-Storm

- Jackson, G., Patel, S., & Khan, S. (2012). Assessing the problem of counterfeit medications in the United Kingdom. *International Journal of Clinical Practice*, 66(3), 241–250. <https://doi.org/10.1111/j.1742-1241.2011.02826.x>
- Jahan, M. S., Islam, M. J., Begum, R., Kayesh, R., & Rahman, A. (2014). A study of method development, validation, and forced degradation for simultaneous quantification of paracetamol and ibuprofen in pharmaceutical dosage form by RP-HPLC method. *Analytical Chemistry Insights*, 9(1), 75–81. <https://doi.org/10.4137/Aci.s18651>
- Jozwiak-Bebenista, M., & Nowak, J. Z. (2014). Paracetamol: Mechanism of action, applications and safety concern. *Acta Poloniae Pharmaceutica - Drug Research*, 71(1), 11–23.
- Kang, J.-C., T.C, W., D.P, W., F.Y, L., X.Y, Z., & Kang, J. . (2016). Multigene phylogeny and HPLC analysis reveal fake *Ophiocordyceps sinensis* in markets. *Mycosphere*, 7(6). <https://doi.org/10.5943/mycosphere/7/6/16>
- Kohler, J. C., Martinez, M. G., Petkov, M., & Sale, J. (2016). *Corruption in the Pharmaceutical Sector - Diagnosing the challenges*. Transparency International UK. Retrieved from <https://www.transparency.org.uk/publications/corruption-in-the-pharmaceutical-sector/>
- Lawson, G. (2014). Counterfeit Tablet Investigations: Can ATR FT/IR Provide Rapid Targeted Quantitative Analyses? *Journal of Analytical & Bioanalytical Techniques*, 5(6). <https://doi.org/10.4172/2155-9872.1000214>
- Lawson, G., Ogwu, J., & Tanna, S. (2018). Quantitative screening of the pharmaceutical ingredient for the rapid identification of substandard and falsified medicines using reflectance infrared spectroscopy. *PloS One*, 13(8), e0202059. <https://doi.org/10.1371/journal.pone.0202059>
- Mallah, M. A., Sherazi, S. T. H., Bhanger, M. I., Mahesar, S. A., & Bajeer, M. A. (2015). A rapid Fourier-transform infrared (FTIR) spectroscopic method for direct quantification of paracetamol content in solid pharmaceutical formulations. *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, 141, 64–70. <https://doi.org/10.1016/j.saa.2015.01.036>
- Man, C. N., Gam, L.-H., Ismail, S., Lajis, R., & Awang, R. (2006). Simple, rapid and sensitive assay method for simultaneous quantification of urinary nicotine and cotinine using gas chromatography–mass spectrometry. *Journal of*

- Chromatography B*, 844(2), 322–327.
<https://doi.org/10.1016/J.JCHROMB.2006.07.029>
- Maurin, J. K., Pluciński, F., Mazurek, A. P., & Fijałek, Z. (2007). The usefulness of simple X-ray powder diffraction analysis for counterfeit control—The Viagra® example. *Journal of Pharmaceutical and Biomedical Analysis*, 43(4), 1514–1518. <https://doi.org/10.1016/J.JPBA.2006.10.033>
- MIMS Malaysia. (n.d.). Paracetamol: Indication, Dosage, Side Effect, Precaution | MIMS.com Malaysia. Retrieved December 13, 2018, from <https://www.mims.com/malaysia/drug/info/paracetamol?mtype=generic>
- National Poison Center. (2006). Procedure for Method Validation.
- Nayyar, G. M. L., Breman, J. G., Newton, P. N., & Herrington, J. (2012). Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. *The Lancet Infectious Diseases*, 12(6), 488–496. [https://doi.org/10.1016/S1473-3099\(12\)70064-6](https://doi.org/10.1016/S1473-3099(12)70064-6)
- Newton, P. N., Green, M. D., & Fernández, F. M. (2010). Impact of poor-quality medicines in the “developing” world. *Trends in Pharmacological Sciences*, 31(3), 99–101. <https://doi.org/10.1016/j.tips.2009.11.005>
- Newton, P. N., Green, M. D., Fernández, F. M., Day, N. P., & White, N. J. (2006). Counterfeit anti-infective drugs. *Lancet Infectious Diseases*, 6(9), 602–613. [https://doi.org/10.1016/S1473-3099\(06\)70581-3](https://doi.org/10.1016/S1473-3099(06)70581-3)
- Ng, C. (2014). Five per cent of medicines in Malaysia are counterfeit - Pfizer | Astro Awani. Retrieved September 29, 2018, from <http://english.astroawani.com/malaysia-news/five-cent-medicines-malaysia-are-counterfeit-pfizer-48197>
- Pappula, N., & Chintala, P. (2014). Development and validation of RP-HPLC method for the simultaneous estimation of paracetamol and flupirtine maleate in pharmaceutical dosage form. *Indian Journal of Pharmaceutical Education and Research*, 48(4), 34–39. <https://doi.org/10.5530/ijper.48.4s.5>
- Petersen, A., Held, N., & Heide, L. (2017). Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab. *PLoS ONE*, 12(9), 1–22. <https://doi.org/10.1371/journal.pone.0184165>
- Rodomonte, A. L., Gaudiano, M. C., Antoniella, E., Lucente, D., Crusco, V., Bartolomei, M., ... Muleri, N. (2010). Counterfeit drugs detection by measurement of tablets and secondary packaging colour. *Journal of*

- Pharmaceutical and Biomedical Analysis*, 53(2), 215–220.
<https://doi.org/10.1016/j.jpba.2010.03.044>
- Rote, A. R., Kumbhoje, P. A., & Bhambar, R. S. (2012). UV-visible spectrophotometric simultaneous estimation of paracetamol and nabumetone by AUC method in combined tablet dosage form. *Pharmaceutical Methods*, 3(1), 40–43. <https://doi.org/10.4103/2229-4708.97722>
- Said, M. M., Gibbons, S., Moffat, A. C., & Zloh, M. (2011). Near-infrared spectroscopy (NIRS) and chemometric analysis of Malaysian and UK paracetamol tablets: A spectral database study. *International Journal of Pharmaceutics*, 415(1–2), 102–109.
<https://doi.org/10.1016/j.ijpharm.2011.05.057>
- Salim, M. R. (2014). Counterfeit medicines. Retrieved September 29, 2018, from <http://www.myhealth.gov.my/en/counterfeit-medicines-2/>
- Saljoughian, M. (2016). Acetaminophen Intoxication: A Critical-Care Emergency.
- Sanagi, M. M., Ling, S. L., Nasir, Z., Hermawan, D., Wan Ibrahim, W. A., & Naim, A. A. (2009). Comparison of signal-to-noise, blank determination, and linear regression methods for the estimation of detection and quantification limits for volatile organic compounds by gas chromatography. *Journal of AOAC International*, 92(6), 1833–1838.
<https://doi.org/10.1001/journal.pgen.1000113>
- Seiter, A. (2009). Health and economic consequences of counterfeit drugs. *Clinical Pharmacology and Therapeutics*, 85(6), 576–578.
<https://doi.org/10.1038/clpt.2009.47>
- Shah, J., Tiantian Li, & Sharma, A. (2015). HPLC Analysis of Acetaminophen Tablets with Waters Alliance and Agilent Supplies. *Agilent Technologies*, 1–5. Retrieved from <https://www.agilent.com/cs/library/applications/5991-6017EN.pdf>
- Sheen, C. L., Dillon, J. F., Bateman, D. N., Simpson, K. J., & Macdonald, T. M. (2002). Paracetamol toxicity: epidemiology, prevention and costs to the health-care system. *QJM*, 95(9), 609–619. <https://doi.org/10.1093/qjmed/95.9.609>
- Shi, Y.-Q., Yao, J., Liu, F., Hu, C.-Q., Yuan, J., Zhang, Q.-M., & Jin, S.-H. (2008). Establishment of an HPLC identification system for detection of counterfeit steroidal drugs. *Journal of Pharmaceutical and Biomedical Analysis*, 46(4), 663–669. <https://doi.org/10.1016/J.JPBA.2007.11.034>

- Skoog, D. A., Holler, F. J., & Crouch, S. R. (2007). *Principles of Instrumental Analysis* (6th Edition). Thomson Brooks/Cole.
- Stevens, P., & Mydin, H. H. (2013). Fake medicines in Asia. *Emerging Markets Health Network Briefing*, (1), 1–9. Retrieved from <http://ideas.org.my/wp-content/uploads/2013/02/EMHN-Fake-Medicine-Asia-Feb-20131.pdf>
- U.S Food & Drug. (n.d.). Counterfeit Medicine. Retrieved September 19, 2018, from <https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/counterfeitmedicine/>
- Wanjau, K., & Muthiani, M. (2012). Factors influencing the influx of counterfeit medicines in Kenya: A survey of pharmaceutical importing small and medium enterprises within Nairobi. *International Journal of Business and Public Management*, 2(2), 23–29. Retrieved from www.journals.mku.ac.ke
- Wertheimer, A. I., & Norris, J. (2009). Safeguarding against substandard/counterfeit drugs: Mitigating a macroeconomic pandemic. *Research in Social and Administrative Pharmacy*, 5(1), 4–16.
<https://doi.org/10.1016/j.sapharm.2008.05.002>
- World Health Organization. (n.d.). Definitions of Substandard and Falsified (SF) Medical Products. Retrieved September 18, 2018, from <http://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products>
- World Health Organization. (2010). *Sixty-Third World Health Assembly - A63/23 - Counterfeit Medical Products*. WHO (Vol. A63/23). Retrieved from http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_23-en.pdf
- Zulkifli, N. W., Aziz, N. A., Hassan, Y., & Hassali, M. A. (2016). Are We on the Right Track?: Overview of Unregistered Drugs in Malaysia. *Journal of Pharmacy Practice and Community Medicine*, 2(4), 107–115.
<https://doi.org/10.5530/jppcm.2016.4.2>
- Zulkifli, N. W., Aziz, N. A., Hassan, Y., Hassali, M. A., & Bahrin, N. L. Z. (2016a). Do current awareness and educational program towards unregistered drugs effective for public? Pharmacists' perceptive. *International Journal of Pharmacy and Pharmaceutical Sciences*, 8(7), 81–85.
- Zulkifli, N. W., Aziz, N. A., Hassan, Y., Hassali, M. A., & Bahrin, N. L. Z. (2016b). The Development of the Problem Solving Framework in Managing Unregistered Drugs: Pharmacists Perspectives. *Journal of Pharmacy Practice*

and Community Medicine, 2(4). <https://doi.org/10.5530/jppcm.2016.4.4>
Zulkifli, N. W., Hassan, Y., Hassali, M. A., Liyana, N., Bahrin, Z., Alam, B. P.,
Alam, B. P. (2016). Publics ' Perceptive on Buying the Unregistered Drugs :
Constant Comparative Method. *Health Policy*, (July).